Physician profile
Daniel C Mcdyer
NPI 1184617839
$3,111.98
in general payments reported to CMS, 2019-2025
32 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $120 · 2021: $435 · 2022: $524 · 2023: $417 · 2024: $413 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $751.97 | 2019 | |
| Evofem Biosciences, INC. | $605.85 | 2021-2024 | Phexxi |
| Mayne Pharma Commercial LLC | $244.67 | 2021-2025 | |
| Exeltis, USA INC. | $207.16 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $161.30 | 2020-2025 | Aptima, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $127.82 | 2019-2025 | |
| Lupin INC. | $102.50 | 2019-2021 | |
| Abbvie INC. | $83.09 | 2021-2022 | |
| Lsi Solutions INC | $68.52 | 2023-2025 | Fornisee, Ti-Knot, Running Device |
| Becton, Dickinson and Company | $61.90 | 2021-2025 | Bd Onclarity |
| Astellas Pharma US INC | $59.38 | 2023-2024 | Veozah |
| Millicent US INC | $59.35 | 2019-2025 | Intrarosa, Femring |
| Therapeuticsmd, INC. | $58.58 | 2021-2022 | |
| Exact Sciences Corporation | $53.10 | 2023-2025 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $50.43 | 2021-2024 | Twirla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $49.02 | 2021-2022 | |
| Pfizer INC. | $45.22 | 2021-2023 | |
| Daiichi Sankyo INC. | $44.77 | 2019-2021 | |
| Shield Therapeutics INC | $38.44 | 2023 | Accrufer |
| Scynexis, INC. | $30.53 | 2022 | |
| Amag Pharmaceuticals, INC. | $28.14 | 2019-2020 | |
| Dysis Medical, INC. | $27.19 | 2021-2022 | |
| Covidien LP | $26.73 | 2019 | |
| Roche Diagnostics Corporation | $22.28 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $20.29 | 2023 | Exparel |
| Sumitomo Pharma America, INC. | $19.11 | 2024 | Myfembree |
| Allergan, INC. | $16.72 | 2020 | |
| Organon LLC | $14.33 | 2022 | |
| Avion Pharmaceuticals | $12.49 | 2020 | |
| Smith+Nephew, INC. | $11.74 | 2019 | |
| Allotrope Medical, INC | $9.36 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mcdyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.